Author: BCW / NOVO NORDISK

Posted Date:

March 31, 2026

Novo Nordisk launches first and only multi-month subscription program for FDA-approved Wegovy®, offering savings of up to $1,200/year

BCW / NOVO NORDISK

March 31, 2026
FDA approves Novo Nordisk’s Awiqli®, the first and only once-weekly basal insulin treatment for adults with type 2 diabetes

BCW / NOVO NORDISK

March 26, 2026
FDA approves Novo Nordisk’s Sogroya® as the first and only once-weekly, long-acting growth hormone for three additional pediatric indications

BCW / NOVO NORDISK

February 27, 2026